FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2987234802> ?p ?o ?g. }

• W2987234802 endingPage "5830" @default.
• W2987234802 startingPage "5830" @default.
• W2987234802 abstract "Introduction: High dose therapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) followed by autologous hematopoietic stem cell transplantation (AHCT) is the most common consolidation therapy for chemosensitive patients with relapsed/refractory Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL) in the US. Inpatient hospitalization is usually required due to the twice daily dosing of etoposide and cytarabine, and patients remain admitted until neutrophil recovery. Utilizing our outpatient transplant program, we aimed to evaluate the feasibility and safety of outpatient BEAM with AHCT using daily dosed etoposide and cytarabine to enhance the patient experience and improve inpatient resource utilization. Methods: We performed a retrospective evaluation of patients treated in the outpatient setting at Memorial Sloan Kettering Cancer Center. Patients were eligible for outpatient AHCT if they did not have a clinical indication for inpatient continuous monitoring. Patients received BEAM conditioning consisting of carmustine on day -6 (300mg/m2), etoposide daily from day -5 through day -2 (200mg/m2/dose), cytarabine daily from day -5 through day -2 (400mg/m2/dose), and melphalan on day -1 (140mg/m2). AHCT on day 0, pegfilgrastim on Day +1, and supportive care were performed as per standard of care and institutional guidelines. Patients were seen daily by an advanced practice provider and HCT attending. Notably, service guidelines were revised to include a delayed emesis prophylactic regimen of oral dexamethasone (2mg bid) and lorazepam (0.5mg TID) from D+1 through D+7, which was initiated after the first three patients were treated. Patients were transfused packed red blood cells (pRBC) for hemoglobin <7g/dl and platelets for <20K/mcl. Results: From October 2018 to July of 2019, 13 patients (Hodgkin's lymphoma (n=5), mantle cell lymphoma (n=4), diffuse large B-cell lymphoma (n=2), T-cell lymphoma (n=2), and grey zone lymphoma (n=1)) were treated. The median age was 40 years (range 26-71), and the majority were male (69%). Median cell dose infused was 5.89 CD34+ cells/kg (range 2.53-10.66). Two patients received cell infusions over 2 days, and three patients received washed cell infusion products. Two patients completed transplant entirely outpatient; the remainder required hospitalization during their transplant course. Reasons for admission included neutropenic fever (n=4), nausea (n=2), tachycardia (n=2), hypoxia (n=1), and other (n=2). Patients were admitted on a median of Day +6 (range Day+1 - Day+11) and remained inpatient for a median of 4 days (range 3-14). Eight patients (62%) returned to the outpatient stem cell transplant clinic for management prior to day 30. One patient was re-hospitalized prior to day 30. The median number of hospital days saved was 13 days/per patient. In total, 170 hospital days were saved with this regimen. Engraftment and toxicities were similar to inpatient administration. Neutrophil engraftment occurred at a median of Day+9 (range 8-11) with a median of 6 days of ANC<500 (IQR 8-11). Platelets comprised most of the transfusion support required, with a median of 4 platelet (range 2-8) and 2 pRBC (range 0-2) transfusions per patient. Grade 2 or higher diarrhea occurred for a median of 3.5 days (range 3-11) with 38% not having any diarrhea. A small percentage of patients required additional antiemetics outside the standard of care (23%). The median weight lost per patient was 2.5kg (range 0 - 10.3kg). Patients received intravenous fluid support with a median of 5 normal saline boluses (range 1-10). All patients maintained normal serum creatinine peri-transplant, with a median maximum serum creatinine of 0.9mg/dl (range 0.7-1.1). Six patients (46%) had engraftment syndrome. All patients were alive with a median follow-up of 91 days (range: 29-205). Conclusion: We found that BEAM followed by AHCT using daily dosed etoposide and cytarabine is feasible and safe for the outpatient setting with tolerability matching that of the traditional inpatient BEAM regimen. Moreover, this treatment method has the potential to reduce a considerable number of inpatient hospital days, while still safely maintaining a threshold for toxicity requiring inpatient admission. Disclosures Bhatt: Incyte: Consultancy. Landau:Pfizer: Membership on an entity's Board of Directors or advisory committees; Caelum: Membership on an entity's Board of Directors or advisory committees; Prothena: Membership on an entity's Board of Directors or advisory committees; Amgen: Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Consultancy, Honoraria. Scordo:Angiocrine Bioscience, Inc.: Consultancy; McKinsey & Company: Consultancy. Sauter:Juno Therapeutics: Consultancy, Research Funding; Kite/Gilead: Consultancy; Precision Biosciences: Consultancy; Genmab: Consultancy; Spectrum Pharmaceuticals: Consultancy; GSK: Consultancy; Celgene: Consultancy; Novartis: Consultancy; Sanofi-Genzyme: Consultancy, Research Funding. Giralt:Celgene: Consultancy, Research Funding; Takeda: Consultancy; Sanofi: Consultancy, Research Funding; Amgen: Consultancy, Research Funding. Shah:Amgen: Research Funding; Janssen: Research Funding." @default.
• W2987234802 created "2019-11-22" @default.
• W2987234802 creator A5001300713 @default.
• W2987234802 creator A5003055083 @default.
• W2987234802 creator A5004396499 @default.
• W2987234802 creator A5009615956 @default.
• W2987234802 creator A5021595775 @default.
• W2987234802 creator A5029524291 @default.
• W2987234802 creator A5030998313 @default.
• W2987234802 creator A5034628611 @default.
• W2987234802 creator A5039653102 @default.
• W2987234802 creator A5041790580 @default.
• W2987234802 creator A5043510888 @default.
• W2987234802 creator A5045167741 @default.
• W2987234802 creator A5045968368 @default.
• W2987234802 creator A5047384277 @default.
• W2987234802 creator A5054038582 @default.
• W2987234802 creator A5056667863 @default.
• W2987234802 creator A5068102821 @default.
• W2987234802 creator A5070096873 @default.
• W2987234802 creator A5085086543 @default.
• W2987234802 creator A5088530030 @default.
• W2987234802 date "2019-11-13" @default.
• W2987234802 modified "2023-09-26" @default.
• W2987234802 title "Outpatient BEAM Using Daily Etoposide and Cytarabine with Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Is Feasible and Decreases Inpatient Length of Stay" @default.
• W2987234802 doi "https://doi.org/10.1182/blood-2019-127402" @default.
• W2987234802 hasPublicationYear "2019" @default.
• W2987234802 type Work @default.
• W2987234802 sameAs 2987234802 @default.
• W2987234802 citedByCount "3" @default.
• W2987234802 countsByYear W29872348022021 @default.
• W2987234802 countsByYear W29872348022023 @default.
• W2987234802 crossrefType "journal-article" @default.
• W2987234802 hasAuthorship W2987234802A5001300713 @default.
• W2987234802 hasAuthorship W2987234802A5003055083 @default.
• W2987234802 hasAuthorship W2987234802A5004396499 @default.
• W2987234802 hasAuthorship W2987234802A5009615956 @default.
• W2987234802 hasAuthorship W2987234802A5021595775 @default.
• W2987234802 hasAuthorship W2987234802A5029524291 @default.
• W2987234802 hasAuthorship W2987234802A5030998313 @default.
• W2987234802 hasAuthorship W2987234802A5034628611 @default.
• W2987234802 hasAuthorship W2987234802A5039653102 @default.
• W2987234802 hasAuthorship W2987234802A5041790580 @default.
• W2987234802 hasAuthorship W2987234802A5043510888 @default.
• W2987234802 hasAuthorship W2987234802A5045167741 @default.
• W2987234802 hasAuthorship W2987234802A5045968368 @default.
• W2987234802 hasAuthorship W2987234802A5047384277 @default.
• W2987234802 hasAuthorship W2987234802A5054038582 @default.
• W2987234802 hasAuthorship W2987234802A5056667863 @default.
• W2987234802 hasAuthorship W2987234802A5068102821 @default.
• W2987234802 hasAuthorship W2987234802A5070096873 @default.
• W2987234802 hasAuthorship W2987234802A5085086543 @default.
• W2987234802 hasAuthorship W2987234802A5088530030 @default.
• W2987234802 hasBestOaLocation W29872348021 @default.
• W2987234802 hasConcept C126322002 @default.
• W2987234802 hasConcept C141071460 @default.
• W2987234802 hasConcept C143998085 @default.
• W2987234802 hasConcept C2776694085 @default.
• W2987234802 hasConcept C2778041864 @default.
• W2987234802 hasConcept C2778119113 @default.
• W2987234802 hasConcept C2778684742 @default.
• W2987234802 hasConcept C2780147359 @default.
• W2987234802 hasConcept C2781413609 @default.
• W2987234802 hasConcept C2911091166 @default.
• W2987234802 hasConcept C71924100 @default.
• W2987234802 hasConceptScore W2987234802C126322002 @default.
• W2987234802 hasConceptScore W2987234802C141071460 @default.
• W2987234802 hasConceptScore W2987234802C143998085 @default.
• W2987234802 hasConceptScore W2987234802C2776694085 @default.
• W2987234802 hasConceptScore W2987234802C2778041864 @default.
• W2987234802 hasConceptScore W2987234802C2778119113 @default.
• W2987234802 hasConceptScore W2987234802C2778684742 @default.
• W2987234802 hasConceptScore W2987234802C2780147359 @default.
• W2987234802 hasConceptScore W2987234802C2781413609 @default.
• W2987234802 hasConceptScore W2987234802C2911091166 @default.
• W2987234802 hasConceptScore W2987234802C71924100 @default.
• W2987234802 hasIssue "Supplement_1" @default.
• W2987234802 hasLocation W29872348021 @default.
• W2987234802 hasOpenAccess W2987234802 @default.
• W2987234802 hasPrimaryLocation W29872348021 @default.
• W2987234802 hasRelatedWork W1987749566 @default.
• W2987234802 hasRelatedWork W2036363303 @default.
• W2987234802 hasRelatedWork W2036869970 @default.
• W2987234802 hasRelatedWork W2057718244 @default.
• W2987234802 hasRelatedWork W2563189124 @default.
• W2987234802 hasRelatedWork W2887364739 @default.
• W2987234802 hasRelatedWork W2911306825 @default.
• W2987234802 hasRelatedWork W3156198912 @default.
• W2987234802 hasRelatedWork W4212897594 @default.
• W2987234802 hasRelatedWork W3022790618 @default.
• W2987234802 hasVolume "134" @default.
• W2987234802 isParatext "false" @default.
• W2987234802 isRetracted "false" @default.
• W2987234802 magId "2987234802" @default.
• W2987234802 workType "article" @default.